Abstract

Background

People who inject drugs (PWID) are at high risk of severe wounds, invasive infections, and overdoses. To date, there are few data on the bacterial and chemical contaminants PWID are exposed to when using illicitly manufactured fentanyls and stimulants.

Methods

Previously used injection drug use equipment was recovered in St Louis, Missouri, by harm reduction organizations over a 12-month period. Syringe residue was analyzed for bacterial contaminants by routine culturing followed by whole genome sequencing of single bacterial isolates. Chemical adulterants in syringe residue were identified by liquid chromatography–mass spectrometry.

Results

Bacteria were cultured from 58.75% of 160 syringes analyzed. Polymicrobial growth was common and was observed in 23.75% of samples. Bacillus cereus was the most common pathogen present and was observed in 20.6% of syringe residues, followed closely by Staphylococcus aureus at 18.8%. One hundred syringes underwent mass spectrometry, which demonstrated that chemical adulterants were common and included caffeine, diphenhydramine, lidocaine, quinine, and xylazine.

Conclusions

Analysis of syringe residue from discarded drug use equipment demonstrates both chemical and biological contaminants, including medically important pathogens and adulterants.

Most overdose deaths in the United States (US) involve illicitly manufactured fentanyls, heroin, cocaine, or methamphetamine (either alone or in combination) [1, 2]. Due to their unregulated nature, the majority of illicit drugs are manufactured, stored, and distributed in nonsterile conditions, potentially facilitating the introduction of bacterial pathogens and contamination with chemical adulterants. The result is a surging syndemic of overdoses, severe wounds, and invasive infections among people who use drugs. People who inject drugs (PWID) in particular are at grave risk of a range of infectious complications, with up to 68% [3] experiencing the spectrum of minor skin and soft tissue infections to life-threatening endovascular infections [4].

Data on the microbial diversity of bacterial pathogens causing infections among PWID is generally limited to epidemiologic trends of infective endocarditis in populations with opioid use disorder or hepatitis C virus [5, 6], or small case series [7]. Outbreaks of harmful pathogens linked to illicit drugs have ranged from uncommon pathogens such as Bacillus anthracis [8] to more ubiquitous organisms such as Staphylococcus aureus [9–11]. Relatively little information exists on the potential sources of most infections among PWID, and data on the risk posed by bacterial contamination of drugs or drug use equipment is lacking. The existing literature is limited to several small studies on the microflora of heroin conducted in the 1970s and 1980s [12–14] and again in 2002 [15]. These previous reports documented high levels of bacterial contaminants; however, over the subsequent 2 decades the risk of bacterial infection from the drug supply itself has been largely ignored. Interestingly, heroin as well as quinine (a common heroin adulterant) was reported to have limited antibacterial properties [16]. Public health messaging on infection prevention has therefore focused almost exclusively on the risk posed by reuse and licking of needles and failure to clean skin sites [17]. With the ever-increasing number of infectious complications occurring among PWID, it is important to understand how prior data on bacterial contamination of heroin samples relate 2 decades later to the current US illicit drug supply that is composed largely of illicitly manufactured fentanyls and stimulants.

Similarly, there is also increasing awareness of the potential for novel chemical adulterants within the illicit drug supply that may harm consumers. While increases in drug overdose deaths have largely been driven by illicitly manufactured fentanyls and their variable concentrations within illicit drug supplies [1, 2], there has been a recent rise in xylazine-positive overdose deaths [18]. Despite these concerning trends, active surveillance of chemical contaminants in illicit controlled substances has historically been limited to medical examiner reports and law enforcement seizures, which investigate chemical compositions of substances only after adverse events have occurred. A growing number of drug-checking programs are emerging; however, these generally only receive batches of illicit drugs after community members witness unusual reactions, and they do not include bacteriologic assessments. This status quo may miss critical surveillance of harmful adulterants and pathogens until after adverse outcomes are widely recognized within the local community. Syringe residue analysis offers an antidote to many of these concerns by offering a wider view of compounds and pathogens circulating within an injection drug use community [19].

To evaluate the potential bacterial and chemical contaminants PWID are exposed to in the local illicit drug supply, we used mass spectrometry, along with microbiologic cultures of syringe residue from discarded drug use equipment collected by harm reduction organizations in St Louis, Missouri, over a 12-month time period from 2022 to 2023.

METHODS

Sample Collection

Discarded injection drug use needles and syringe equipment was collected from sharps containers provided by street medicine outreach and harm reduction teams from Street Med STL, a volunteer street medicine and harm reduction organization that provides care to unhoused persons who use drugs. Outreach occurred weekly over a 12-month time period at 5 different sites in St Louis, Missouri. Sharps were only collected if properly disposed of in a sharps container (no loose refuse was obtained). Once collected, sharps containers were transferred to research laboratories at Washington University in St Louis. Forceps were used to safely remove only capped syringes, in order to reduce the chance that any pathogens cultured in this analysis could stem from the external environment within the sharps container. All other injection drug use equipment was discarded and not included in the analysis. Time from collection by Street Med STL to processing by laboratory workers for bacterial culture analysis was within 1 week.

Bacterial Culturing and Analysis

The capped needle-syringe combinations were cultured by removing the plunger on the back of the syringe and inserting a sterile culture swab (BD ESwab), which was plated on a variety of culture media and culture conditions including blood agar, MacConkey agar, Escherichia coli Coliform Selective Agar (Millipore Sigma), and mannitol salt phenol red agar (Millipore Sigma), and incubated under both routine and anaerobic conditions at 37°C. Unique colony morphotypes from individual plates were identified and broth enrichment was performed in Luria-Bertani broth, THY medium (Todd-Hewitt broth with 2% yeast extract), or tryptic soy broth. Genomic DNA was extracted from pure cultures using the Puregene Yeast/Bacteria Genome Purification Kit (Qiagen, Hilden, Germany). As S aureus colonies could be immediately identified due to their coloration on mannitol salt phenol red agar, relative abundance of these was also recorded.

Whole Genome Sequencing

Whole genomic DNA was submitted for shotgun sequencing to an average depth of 1.8 million reads (100–200× genome coverage) on the NovaSeq 6000. Raw sequencing reads were trimmed of adaptors using trimmomatic, human DNA contamination was removed with Deconseq, files were repaired with bbmap, and genomes were assembled with Unicycler. CheckM and Quast were used to check genome statistics. Assemblies were retained if they were >90% complete with <5% contamination. Mash was used to assign taxonomy.

Liquid Chromatography–Mass Spectrometry

Mass spectrometry analysis was performed for a subset of 100 syringes. Swabs were inserted into 1 mL of mass spectrometry–grade water for 5 minutes and then removed, and the solution was filtered through a 40 µm mesh followed by 2000g centrifugation for 12 minutes. Supernatant was immediately aliquoted into cryovials and stored at −20°C until ready for experimental analysis. Mass spectrometry–grade methanol (mass spectrometry grade, Sigma-Aldrich) was used as a control.

Untargeted mass spectrometry was performed using an Orbitrap ID-X high-resolution accurate mass spectrometer coupled to a Vanquish ultra high performance liquid chromatography mass spectrometer (Thermo Scientific), as described in the Supplementary Materials (Mass Spectrometry Methods). In brief, separation was performed with a reverse phase Waters Acquity HSS T3 column (100 Å, 1.8 µm, 2.1 mm × 150 mm) maintained at 30°C with a constant flow rate of 0.4 mL/minute. Proportions of mobile phase buffers A (0.1% formic acid in H2O) and B (0.1% formic acid and 90% acetonitrile in H2O) were varied according to the following gradient: constant 2% B from 0 to 2 minutes, linear gradient to 27% B at 9 minutes, linear gradient to 98% B at 16 minutes, hold until 18 minutes, back to 2% B at 19 minutes, and equilibration at 2% B until 22 minutes. MS1 scans were collected between 100 and 1000 m/z using the Orbitrap detector with quadrupole isolation and resolution set to 60 000. Further detailed mass spectrometry parameters can be found in the Supplementary Materials (Mass Spectrometry Methods). Identification of features was performed using the automated AcquireX protocol (Thermo Scientific) with comparison to the mzCloud database (Thermo Scientific), as further described in the Supplementary Materials (Mass Spectrometry Methods).

Residue from all 100 syringes was analyzed using multiple reaction monitoring (MRM) targeted mass spectrometry to determine the presence or absence of common illicit substances and adulterants listed in the Supplementary Materials (Mass Spectrometry Methods) and Supplementary Table 1.

MRM was performed using an AB Sciex 4000 QTrap triple-quadrupole mass spectrometer coupled to a Shimadzu UFLC. In brief, separation was performed with a reverse phase Supelco Ascentis Express Phenyl-Hexyl (90 Å, 2.7 µm, 10 cm × 2.1 mm) at room temperature. Total flow rate was set to 0.35 mL/minute. Proportions of mobile phase buffers A (0.1% formic acid in H2O) and B (0.1% formic acid and 90% acetonitrile in H2O) were varied according to the following gradient: constant 2% B from 0 to 1 minutes, linear gradient to 35% B at 23 minutes, linear gradient to 98% B at 24 minutes, hold until 27 minutes, back to 2% B at 28 minutes, and equilibration at 2% B until 31 minutes. Samples were analyzed in positive ion mode, with detailed parameters described in the Supplementary Materials (Mass Spectrometry Methods). US Drug Enforcement Administration–exempt standards were purchased when possible for comparison. Peak calls for presence/absence were manually verified by 3 authors.

Patient Consent Statement

The Washington University School of Medicine Human Research Protection Office designated this activity as non–human subjects research as no identifiable information was collected, and analyses were limited to discarded injection equipment.

RESULTS

Microbiologic Survey of Syringe Residue

A total of 160 syringe residue samples from injection drug use equipment were analyzed. Bacteria were cultured from 94 of the 160 syringes analyzed (58.75%). Polymicrobial growth was common and was observed in 38 of the 160 samples (23.75%) analyzed. The list of all bacterial species isolated is shown in Table 1. Medically important pathogens cultured from syringe residue included Acinetobacter spp, Bacillus cereus, Enterobacter spp, Klebsiella spp, Pseudomonas spp, Serratia marcescens, S aureus, and coagulase-negative staphylococci. Bacillus cereus was the most common pathogen present, observed in 20.6% of syringe residues, followed closely by S aureus at 18.8%.

Table 1.

Bacterial Pathogens Cultured From Syringe Residue of Discarded Injection Drug Use Paraphernalia, Listed in Order of Prevalence

PathogenPrevalence
Bacillus cereus33 (20.6%)
Staphylococcus aureus30 (18.8%)
Bacillus altitudinis14 (8.8%)
Bacillus velezensis11 (6.9%)
Priestia megaterium10 (6.3%)
Bacillus safensis9 (5.6%)
Pseudomonas aeruginosa5 (3.1%)
Bacillus flexus4 (2.5%)
Bacillus licheniformis4 (2.5%)
Exiguobacterium acetylicum4 (2.5%)
Planococcus citreus4 (2.5%)
Bacillus pumilus2 (1.3%)
Brucella intermedia2 (1.3%)
Acinetobacter variabilis1 (0.6%)
Aerococcus urinaeequi1 (0.6%)
Microbacterium paraoxydans2 (1.3%)
Microbacterium sp2 (1.3%)
Staphylococcus capitis2 (1.3%)
Bacillus aryabhattai1 (0.6%)
Bacillus nealsonii1 (0.6%)
Brachybacterium paraconglomeratum1 (0.6%)
Brevibacillus centrosporus1 (0.6%)
Brevibacillus parabrevis1 (0.6%)
Cellulosimicrobium cellulans1 (0.6%)
Cytobacillus sp1 (0.6%)
Enterobacter hormaechei1 (0.6%)
Enterobacter sp1 (0.6%)
Klebsiella michiganensis1 (0.6%)
Kocuria carniphila1 (0.6%)
Kocuria polaris1 (0.6%)
Leclercia adecarboxylata1 (0.6%)
Lysinibacillus boronitolerans1 (0.6%)
Paenibacillus polymyxa1 (0.6%)
Paenibacillus sp1 (0.6%)
Pseudomonas oryzihabitans1 (0.6%)
Pseudomonas otitidis1 (0.6%)
Serratia marcescens1 (0.6%)
Sphingomonas dokdonensis1 (0.6%)
Staphylococcus epidermidis1 (0.6%)
Staphylococcus hominis1 (0.6%)
Staphylococcus xylosus1 (0.6%)
PathogenPrevalence
Bacillus cereus33 (20.6%)
Staphylococcus aureus30 (18.8%)
Bacillus altitudinis14 (8.8%)
Bacillus velezensis11 (6.9%)
Priestia megaterium10 (6.3%)
Bacillus safensis9 (5.6%)
Pseudomonas aeruginosa5 (3.1%)
Bacillus flexus4 (2.5%)
Bacillus licheniformis4 (2.5%)
Exiguobacterium acetylicum4 (2.5%)
Planococcus citreus4 (2.5%)
Bacillus pumilus2 (1.3%)
Brucella intermedia2 (1.3%)
Acinetobacter variabilis1 (0.6%)
Aerococcus urinaeequi1 (0.6%)
Microbacterium paraoxydans2 (1.3%)
Microbacterium sp2 (1.3%)
Staphylococcus capitis2 (1.3%)
Bacillus aryabhattai1 (0.6%)
Bacillus nealsonii1 (0.6%)
Brachybacterium paraconglomeratum1 (0.6%)
Brevibacillus centrosporus1 (0.6%)
Brevibacillus parabrevis1 (0.6%)
Cellulosimicrobium cellulans1 (0.6%)
Cytobacillus sp1 (0.6%)
Enterobacter hormaechei1 (0.6%)
Enterobacter sp1 (0.6%)
Klebsiella michiganensis1 (0.6%)
Kocuria carniphila1 (0.6%)
Kocuria polaris1 (0.6%)
Leclercia adecarboxylata1 (0.6%)
Lysinibacillus boronitolerans1 (0.6%)
Paenibacillus polymyxa1 (0.6%)
Paenibacillus sp1 (0.6%)
Pseudomonas oryzihabitans1 (0.6%)
Pseudomonas otitidis1 (0.6%)
Serratia marcescens1 (0.6%)
Sphingomonas dokdonensis1 (0.6%)
Staphylococcus epidermidis1 (0.6%)
Staphylococcus hominis1 (0.6%)
Staphylococcus xylosus1 (0.6%)
Table 1.

Bacterial Pathogens Cultured From Syringe Residue of Discarded Injection Drug Use Paraphernalia, Listed in Order of Prevalence

PathogenPrevalence
Bacillus cereus33 (20.6%)
Staphylococcus aureus30 (18.8%)
Bacillus altitudinis14 (8.8%)
Bacillus velezensis11 (6.9%)
Priestia megaterium10 (6.3%)
Bacillus safensis9 (5.6%)
Pseudomonas aeruginosa5 (3.1%)
Bacillus flexus4 (2.5%)
Bacillus licheniformis4 (2.5%)
Exiguobacterium acetylicum4 (2.5%)
Planococcus citreus4 (2.5%)
Bacillus pumilus2 (1.3%)
Brucella intermedia2 (1.3%)
Acinetobacter variabilis1 (0.6%)
Aerococcus urinaeequi1 (0.6%)
Microbacterium paraoxydans2 (1.3%)
Microbacterium sp2 (1.3%)
Staphylococcus capitis2 (1.3%)
Bacillus aryabhattai1 (0.6%)
Bacillus nealsonii1 (0.6%)
Brachybacterium paraconglomeratum1 (0.6%)
Brevibacillus centrosporus1 (0.6%)
Brevibacillus parabrevis1 (0.6%)
Cellulosimicrobium cellulans1 (0.6%)
Cytobacillus sp1 (0.6%)
Enterobacter hormaechei1 (0.6%)
Enterobacter sp1 (0.6%)
Klebsiella michiganensis1 (0.6%)
Kocuria carniphila1 (0.6%)
Kocuria polaris1 (0.6%)
Leclercia adecarboxylata1 (0.6%)
Lysinibacillus boronitolerans1 (0.6%)
Paenibacillus polymyxa1 (0.6%)
Paenibacillus sp1 (0.6%)
Pseudomonas oryzihabitans1 (0.6%)
Pseudomonas otitidis1 (0.6%)
Serratia marcescens1 (0.6%)
Sphingomonas dokdonensis1 (0.6%)
Staphylococcus epidermidis1 (0.6%)
Staphylococcus hominis1 (0.6%)
Staphylococcus xylosus1 (0.6%)
PathogenPrevalence
Bacillus cereus33 (20.6%)
Staphylococcus aureus30 (18.8%)
Bacillus altitudinis14 (8.8%)
Bacillus velezensis11 (6.9%)
Priestia megaterium10 (6.3%)
Bacillus safensis9 (5.6%)
Pseudomonas aeruginosa5 (3.1%)
Bacillus flexus4 (2.5%)
Bacillus licheniformis4 (2.5%)
Exiguobacterium acetylicum4 (2.5%)
Planococcus citreus4 (2.5%)
Bacillus pumilus2 (1.3%)
Brucella intermedia2 (1.3%)
Acinetobacter variabilis1 (0.6%)
Aerococcus urinaeequi1 (0.6%)
Microbacterium paraoxydans2 (1.3%)
Microbacterium sp2 (1.3%)
Staphylococcus capitis2 (1.3%)
Bacillus aryabhattai1 (0.6%)
Bacillus nealsonii1 (0.6%)
Brachybacterium paraconglomeratum1 (0.6%)
Brevibacillus centrosporus1 (0.6%)
Brevibacillus parabrevis1 (0.6%)
Cellulosimicrobium cellulans1 (0.6%)
Cytobacillus sp1 (0.6%)
Enterobacter hormaechei1 (0.6%)
Enterobacter sp1 (0.6%)
Klebsiella michiganensis1 (0.6%)
Kocuria carniphila1 (0.6%)
Kocuria polaris1 (0.6%)
Leclercia adecarboxylata1 (0.6%)
Lysinibacillus boronitolerans1 (0.6%)
Paenibacillus polymyxa1 (0.6%)
Paenibacillus sp1 (0.6%)
Pseudomonas oryzihabitans1 (0.6%)
Pseudomonas otitidis1 (0.6%)
Serratia marcescens1 (0.6%)
Sphingomonas dokdonensis1 (0.6%)
Staphylococcus epidermidis1 (0.6%)
Staphylococcus hominis1 (0.6%)
Staphylococcus xylosus1 (0.6%)

As S aureus is among the pathogens causing the highest burden of disease in PWID, and colonies could be immediately identified due to their coloration on mannitol salt phenol red agar, the relative abundance of S aureus colonies was also recorded. Among the 30 syringe residues where S aureus was cultured, 7 samples had rare S aureus with between 1 and 10 colony-forming units (CFU) per plate noted when swabs were directly plated from syringe residue onto mannitol salt phenol red agar, 10 samples showed moderate growth with between 10 and 100 CFU per plate, and 13 samples grew abundant S aureus showing a confluent lawn of S aureus too numerous to individually enumerate colonies.

Mass Spectrometry Analysis of Syringe Residue

One hundred syringes from sharps containers collected by Street Med STL during harm reduction outreach were analyzed by liquid chromatography–MRM over the 12-month timespan. To detect potential illicit substances and chemical adulterants in the drug supply, untargeted mass spectrometry was performed on syringes collected during or before January 2023. Untargeted mass spectrometry revealed a wide range of illicit substances and their associated metabolites. These included fentanyl; fentanyl metabolites, analogues, and precursors; methamphetamines; cocaine; benzoylecgonine; heroin; 4-ANPP; tramadol; methcathinone; and ephedrine. Methcathinone, tramadol, and ephedrine were only detected in trace amounts in a small number of syringes and so were not included in targeted scans. Targeted LC-MRMs were developed for the most common illicit substances identified by untargeted mass spectrometry. Of the 100 syringes analyzed by targeted LC-MRMs, 98 of 100 (98%) contained residue of either methamphetamines, fentanyl, or both, confirming that syringes collected for this project were previously used for injection of illicit drugs. Of the 98 syringes that contained drug residue, targeted LC-MRMs detected methamphetamine in 97 (99%) syringes, 1 or more opioids were detected in 83 (85%) syringes, and cocaine was detected in 56 (57%) syringes (Table 2). Among the 83 opioid-positive samples, 83 of 83 (100%) contained fentanyl, 13 of 83 (16%) contained acetyl-fentanyl, and 23 of 82 (28%) contained heroin or the heroin metabolite 6-acetylmorphine.

Table 2.

Illicit Drugs and Medically Important Adulterants Detected in Syringe Residue

Drug GroupSubstancePrevalence (N = 100 Samples)
StimulantsBenzoylecgonine39 (39%)
Cocaine56 (56%)
Methamphetamine97 (97%)
OpioidsFentanyl (including metabolites, analogues, and precursors)83 (83%)
4-ANPP76 (76%)
Heroin13 (13%)
6-Acetylmorphine22 (22%)
Acetylfentanyl13 (13%)
AdulterantsDiphenhydramine83 (83%)
Caffeine59 (59%)
Lidocaine66 (66%)
Levamisole1 (1%)
Quinine52 (52%)
Xylazine58 (58%)
Drug GroupSubstancePrevalence (N = 100 Samples)
StimulantsBenzoylecgonine39 (39%)
Cocaine56 (56%)
Methamphetamine97 (97%)
OpioidsFentanyl (including metabolites, analogues, and precursors)83 (83%)
4-ANPP76 (76%)
Heroin13 (13%)
6-Acetylmorphine22 (22%)
Acetylfentanyl13 (13%)
AdulterantsDiphenhydramine83 (83%)
Caffeine59 (59%)
Lidocaine66 (66%)
Levamisole1 (1%)
Quinine52 (52%)
Xylazine58 (58%)
Table 2.

Illicit Drugs and Medically Important Adulterants Detected in Syringe Residue

Drug GroupSubstancePrevalence (N = 100 Samples)
StimulantsBenzoylecgonine39 (39%)
Cocaine56 (56%)
Methamphetamine97 (97%)
OpioidsFentanyl (including metabolites, analogues, and precursors)83 (83%)
4-ANPP76 (76%)
Heroin13 (13%)
6-Acetylmorphine22 (22%)
Acetylfentanyl13 (13%)
AdulterantsDiphenhydramine83 (83%)
Caffeine59 (59%)
Lidocaine66 (66%)
Levamisole1 (1%)
Quinine52 (52%)
Xylazine58 (58%)
Drug GroupSubstancePrevalence (N = 100 Samples)
StimulantsBenzoylecgonine39 (39%)
Cocaine56 (56%)
Methamphetamine97 (97%)
OpioidsFentanyl (including metabolites, analogues, and precursors)83 (83%)
4-ANPP76 (76%)
Heroin13 (13%)
6-Acetylmorphine22 (22%)
Acetylfentanyl13 (13%)
AdulterantsDiphenhydramine83 (83%)
Caffeine59 (59%)
Lidocaine66 (66%)
Levamisole1 (1%)
Quinine52 (52%)
Xylazine58 (58%)

Initial untargeted mass spectrometry had also revealed a range of medically significant adulterants including caffeine, diphenhydramine, lidocaine, quinine, and xylazine. Standards for medically significant adulterants were obtained for caffeine, diphenhydramine, lidocaine, quinine, and xylazine in order to verify their identity and prevalence within the samples. In addition, a standard for levamisole was purchased as it is a published chemical adulterant. Targeted liquid chromatography–mass spectrometry (LC-MS) runs confirmed that the presence of these chemical adulterants was common in the 98 syringes containing drug residue, including caffeine (59/98 [60%]), diphenhydramine (83/98 [85%]), lidocaine (66/98 [67%]), quinine (52/98 [53%]), and xylazine (58/98 [59%]). Levamisole was uncommon and was only detected in 1 of 98 (1%) syringes containing drug residue where it was found in combination with cocaine. The prevalence of xylazine and quinine among fentanyl-containing syringe residues remained relatively stable over the project period (Supplementary Figure 1).

DISCUSSION

The data presented in this analysis demonstrates that the illicit drug supply in Missouri is contaminated with numerous chemical adulterants, and that a variety of different bacterial pathogens are present in syringe residue. There are several potential points at which bacteria may have been introduced into syringe residue: (1) during the manufacturing process; (2) during the distribution and repackaging within the supply chain; (3) from solvents used in the preparation of illicit drugs immediately prior to injection; (4) during drug mixing and handling; (5) from skin contamination during the injection process; or (6) resulting from draw-back into the syringe if PWID are bacteremic.

Contaminated illicit drugs and unsafe drug preparation practices are a well-described cause of infections in PWID. Prior work conducted in the wake of local outbreaks has cultured B cereus and Clostridium spp from confiscated heroin supplies, offering confirmation of the role of microbial contamination of heroin in causing injection drug use–associated infections [15, 20]. More recently, Kasper et al evaluated previously used cookers for the presence of S aureus and found that 14% of cookers/filters used for injection of opioids were contaminated, raising the possibility that both illicit drugs and drug preparation equipment could serve as sources of infection [21].

Outbreaks of infections linked to contaminated medications can cause severe disease and even deaths. In the US, these have been largely associated with pharmacy-compounded sterile preparations with the most common practices associated with contamination, including compounding originating from nonsterile ingredients and repackaging of already sterile products [22–24]. Breaches in aseptic processing and deficiencies in sterilization procedures or in sterility/endotoxin testing are frequently associated with these infectious outbreaks [23]. The unregulated nature of illicitly manufactured fentanyls and stimulants allows for many of these nonsterile practices, increasing the risk of medication-associated outbreaks among PWID.

Perhaps the most concerning finding in this study is the overall stability and relative abundance of pathogenic bacterial species in syringe residue, highlighting the potential for transmission of bacterial pathogens through sharing of drug use equipment. While many of the bacterial species identified here are environmental organisms not known to cause infections in immunocompetent hosts, a number of important human pathogens that cause both serious skin and soft tissue infections and infective endocarditis in PWID were identified. These included Acinetobacter [25], B cereus [26, 27], Pseudomonas aeruginosa [28], S marcescens [29], S aureus [11], and coagulase-negative staphylococci [7, 30].

Despite a shift in the type of illicit drugs used by PWID from heroin to illicitly manufactured fentanyls and methamphetamines, pathogens isolated from syringe residue in this analysis mirror those previously identified in microbiologic studies of heroin performed in the 1970s, 1980s, and more recently in 2002 [15]. Microflora were composed primarily of endospore-forming bacteria (Bacillus and Paenibacillus spp) as well as staphylococci. Endospore-forming bacteria are frequently present in soil in the environment; and researchers had previously hypothesized that these could be the result of the initial heroin manufacturing process as it was derived from poppies [15]. However, given their presence in the syringe residue of illicitly manufactured fentanyls and stimulants, the source seems more likely to be post-processing contact with the environment or injectors. While staphylococci do not produce endospores, they are known to persist on fomites [31]. All Staphylococcus spp isolated in this analysis are primary colonizers of human skin and thus 1 potential source could be direct contact with the skin flora of the drug producers, processors, distributors, or PWID. Their presence and relative stability in syringe residue along with needle and syringe sharing practices may explain their transmission within the injection drug use network [9, 10]. By focusing on syringe residue from used, capped, needle–syringe combinations, this analysis also captures any adulterants or pathogens introduced by solvents or drug preparation. This may explain the presence of pathogens such as Pseudomonas and Serratia, which are more typically associated with contaminated water and could reflect a lack of access to sterile water for drug preparation.

Several species that commonly cause bloodstream infections in PWID, including streptococci and oral anaerobes, were notably absent from this analysis. Interestingly, they have not been isolated in any investigations of heroin microflora in the past [15]. The ongoing absence of these pathogens may be due to their limited stability on fomites and in syringe residue, or may reflect that these pathogens are introduced into patients only after illicit drugs are prepared, such as through licking needles. If introduced through licking needles, oral streptococci and other oral anaerobes would not be expected to be present in syringe residue and would be only present on the outer surface of the needle itself. Needles were not cultured in this analysis, both to reduce the risk to laboratory workers and to limit the potential that any positive cultures could be the result of handling after injection drug use, or due to environmental pathogens within the sharps container.

Untargeted mass spectrometry analysis of syringe residue revealed the presence of a number of medically important chemical adulterants, which was confirmed with the use of chemical standards by targeted mass spectrometry. More than half of syringes analyzed by LC-MS contained the adulterant xylazine, which has been increasing in prevalence in illicit drug supplies across the US [18, 32] and is associated with severe ulcers and nonhealing wounds [33]. Our analysis also revealed a significant number of other adulterants in syringe residue including caffeine, diphenhydramine, lidocaine, and quinine. The ongoing presence of quinine is important for clinicians to be aware of as overdoses of quinine can result in both cardiovascular toxicity and platelet disorders, including arrhythmias, chest pain, and thrombocytopenia [34]. Although levamisole has been historically documented as a common chemical adulterant of cocaine, of medical importance due to its ability to cause severe vasculitis [35], levamisole was present in only 1 sample. Most syringes demonstrated multiple illicit drugs, suggesting either unintentional poly-drug use or that syringes may have been used on multiple occasions for injecting multiple different drugs. Compared to another recent study analyzing syringe residue from needle-exchange syringes in Washington, District of Columbia (DC) [19], our study found a much higher proportion of syringes positive for methamphetamine, cocaine, and poly-drug contamination. We speculate that may be due to the direct collection of syringes from street encampments, which may represent a population engaging in higher-risk injection behaviors or using multiple substances.

Syringe access programs are evidence-based harm reduction interventions that can provide PWID with safe disposal and exchange of used syringes for new syringes and other supplies [36, 37]. Currently, syringe access programs operate in 44 states as well as Washington, DC and Puerto Rico; however, only 38 states have officially legalized syringe access program operation and Missouri is not among these [38]. The presence of multiple chemical adulterants and bacterial pathogens within syringe residue from St Louis, Missouri, suggests an urgent need for broader and more timely drug-checking services, as well as wider access to sterile harm reduction supplies including those that might be provided by syringe access programs.

This report has several important limitations. As injection drug use equipment was collected through outreach, individual PWIDs may have contributed multiple syringes at any given time. To reduce the likelihood of any individual sample or PWID predominating our results, we collected samples during routine outreach efforts at 5 different sites over a 12-month timespan. Furthermore, by collecting discarded injection drug use equipment over multiple sites and dates during routine harm reduction activities, these data present a more agnostic picture of the bacterial and chemical contaminants in the local drug supply compared to drug use samples submitted to drug-checking programs, which may represent only those samples that individual participants feel are causing unusual harms. Another important limitation is that syringe sharing and reuse is common, particularly among unhoused PWID. This is likely the reason for the high preponderance of syringe residue samples that contained multiple illicit drugs. This analysis cannot distinguish between poly-substance use, serial use of individual substances by an individual person, or syringe sharing.

CONCLUSIONS

Analysis of syringe residue from discarded drug use equipment used by PWID demonstrates both chemical and biological contaminants including medically important pathogens. These data illustrate the strength of syringe residue surveillance to monitor drug trends and how this method can be used to detect emerging chemical contaminants and pathogens in the future.

Supplementary Data

Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Notes

Author contributions. L. R. M., J. A. W., and J. P. H. conceptualized and designed the study. D. J. S. and L. Z. performed the genomic analysis and sequencing. L. R. M., J. A. W., and E. J. conducted all microbiologic studies. J. A. W. and J. L. R. performed all mass spectrometry. N. S. N. and R. J. coordinated harm outreach and interpretation of local drug use trends. All authors had full access to all data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All authors contributed to the writing and critical revision of the report. All authors contributed to the data acquisition, data analysis, or data interpretation and reviewed and approved the final version.

Patient consent. This study was designated non–human subjects research by the Washington University Institutional Review Board before any research activities were performed.

Disclaimer. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.

Financial support. This work was supported in part by funds from the Institute for Public Health at Washington University in St. Louis (to N. S. N.) and the Longer Life Foundation (to L. R. M.). D. J. S. is supported by the Doris Duke Charitable Foundation (Physician Scientist Fellowship grant number 2021081) and the National Institute of Allergy and Infectious Diseases (award number K08 KAI159384). R. J. is supported by the National Institute on Drug abuse (grant number NIDAK12DA050607) and J. P. H. is supported by the National Institute of Diabetes and Digestive and Kidney Diseases (grant number R01DK125860).

References

1

Hedegaard
H
,
Miniño
AM
,
Spencer
MR
,
Warner
M
.
Drug overdose deaths in the United States, 1999–2020
.
NCHS Data Brief
2021
;
426
:
1
8
.

2

Mattson
CL
,
Tanz
LJ
,
Quinn
K
,
Kariisa
M
,
Patel
P
,
Davis
NL
.
Trends and geographic patterns in drug and synthetic opioid overdose deaths—United States, 2013–2019
.
MMWR Morb Mortal Wkly Rep
2021
;
70
:
202
7
.

3

Binswanger
IA
,
Kral
AH
,
Bluthenthal
RN
,
Rybold
DJ
,
Edlin
BR
.
High prevalence of abscesses and cellulitis among community-recruited injection drug users in San Francisco
.
Clin Infect Dis
2000
;
30
:
579
81
.

4

Kadri
AN
,
Wilner
B
,
Hernandez
AV
, et al.
Geographic trends, patient characteristics, and outcomes of infective endocarditis associated with drug abuse in the United States from 2002 to 2016
.
J Am Heart Assoc
2019
;
8
:
e012969
.

5

Wong
CY
,
Zhu
W
,
Aurigemma
GP
, et al.
Infective endocarditis among persons aged 18–64 years living with human immunodeficiency virus, hepatitis C infection, or opioid use disorder, United States, 2007–2017
.
Clin Infect Dis
2021
;
72
:
1767
81
.

6

Ball
LJ
,
Sherazi
A
,
Laczko
D
, et al.
Validation of an algorithm to identify infective endocarditis in people who inject drugs
.
Med Care
2018
;
56
:
e70
5
.

7

Lorson
WC
,
Heidel
RE
,
Shorman
MA
.
Microbial epidemiology of infectious endocarditis in the intravenous drug abuse population: a retrospective study
.
Infect Dis Ther
2019
;
8
:
113
8
.

8

Price
EP
,
Seymour
ML
,
Sarovich
DS
, et al.
Molecular epidemiologic investigation of an anthrax outbreak among heroin users, Europe
.
Emerg Infect Dis
2012
;
18
:
1307
13
.

9

Marks
LR
,
Calix
JJ
,
Wildenthal
JA
, et al.
Staphylococcus aureus injection drug use-associated bloodstream infections are propagated by community outbreaks of diverse lineages
.
Commun Med (Lond)
2021
;
1
:
52
.

10

Packer
S
,
Pichon
B
,
Thompson
S
, et al.
Clonal expansion of community-associated meticillin-resistant Staphylococcus aureus (MRSA) in people who inject drugs (PWID): prevalence, risk factors and molecular epidemiology, Bristol, United Kingdom, 2012 to 2017
.
Euro Surveill
2019
;
24
:
1800124
.

11

Parikh
MP
,
Octaria
R
,
Kainer
MA
.
Methicillin-resistant Staphylococcus aureus bloodstream infections and injection drug use, Tennessee, USA, 2015–2017
.
Emerg Infect Dis
2020
;
26
:
446
53
.

12

Tuazon
CU
,
Hill
R
,
Sheagren
JN
.
Microbiologic study of street heroin and injection paraphernalia
.
J Infect Dis
1974
;
129
:
327
9
.

13

Lewis
RJ
.
Bacteria cultured from heroin paraphernalia
.
J Infect Dis
1974
;
129
:
748
.

14

Moustoukas
NM
,
Nichols
RL
,
Smith
JW
,
Garey
RE
,
Egan
RR
.
Contaminated street heroin. Relationship to clinical infections
.
Archiv Surg
1983
;
118
:
746
9
.

15

McLauchlin
J
,
Mithani
V
,
Bolton
FJ
, et al.
An investigation into the microflora of heroin
.
J Med Microbiol
2002
;
51
:
1001
8
.

16

Tuazon
CU
,
Miller
H
,
Shamsuddin
D
.
Antimicrobial activity of street heroin
.
J Infect Dis
1980
;
142
:
944
.

17

Centers for Disease Control and Prevention
.
Persons who inject drugs—strategies for disease prevention
. Available at: https://www.cdc.gov/pwid/disease-prevention.html. Accessed 1 August 2023.

18

Johnson
J
,
Pizzicato
L
,
Johnson
C
,
Viner
K
.
Increasing presence of xylazine in heroin and/or fentanyl deaths, Philadelphia, Pennsylvania, 2010–2019
.
Inj Prev
2021
;
27
:
395
8
.

19

Evans
A
,
Krause
M
,
Leach
S
,
Levitas
M
,
Nguyen
L
,
Short
LC
.
Analysis of drug residue in needle-exchange syringes in Washington, D.C
.
Forensic Sci Int
2021
;
329
:
111083
.

20

Benusic
MA
,
Press
NM
,
Hoang
LM
,
Romney
MG
.
A cluster of Bacillus cereus bacteremia cases among injection drug users
.
Can J Infect Dis Med Microbiol
2015
;
26
:
103
4
.

21

Kasper
KJ
,
Manoharan
I
,
Hallam
B
, et al.
A controlled-release oral opioid supports S. aureus survival in injection drug preparation equipment and may increase bacteremia and endocarditis risk
.
PLoS One
2019
;
14
:
e0219777
.

22

MacCannell
T
,
Perz
J
,
Srinivasan
A
.
Bacterial and parasitic infections associated with extrinsically contaminated injectable medications, United States 1999–2009 [abstract 604]
. In:
Fifth Decennial International Conference on Healthcare-Associated Infections 2010
.
Atlanta, GA
,
2010
.

23

Shehab
N
,
Brown
MN
,
Kallen
AJ
,
Perz
JF
.
U.S. compounding pharmacy-related outbreaks, 2001–2013: public health and patient safety lessons learned
.
J Patient Saf
2018
;
14
:
164
73
.

24

Patel
PR
,
Larson
AK
,
Castel
AD
, et al.
Hepatitis C virus infections from a contaminated radiopharmaceutical used in myocardial perfusion studies
.
JAMA
2006
;
296
:
2005
11
.

25

Salzer
HJ
,
Rolling
T
,
Schmiedel
S
,
Klupp
EM
,
Lange
C
,
Seifert
H
.
Severe community-acquired bloodstream infection with Acinetobacter ursingii in person who injects drugs
.
Emerg Infect Dis
2016
;
22
:
134
7
.

26

Schaefer
G
,
Campbell
W
,
Jenks
J
, et al.
Persistent Bacillus cereus bacteremia in 3 persons who inject drugs, San Diego, California, USA
.
Emerg Infect Dis
2016
;
22
:
1621
3
.

27

Dancer
SJ
,
McNair
D
,
Finn
P
,
Kolsto
A-B
.
Bacillus cereus cellulitis from contaminated heroin
.
J Med Microbiol
2002
;
51
:
278
81
.

28

Levin
MH
,
Weinstein
RA
,
Nathan
C
,
Selander
RK
,
Ochman
H
,
Kabins
SA
.
Association of infection caused by Pseudomonas aeruginosa serotype O11 with intravenous abuse of pentazocine mixed with tripelennamine
.
J Clin Microbiol
1984
;
20
:
758
62
.

29

McCann
T
,
Elabd
H
,
Blatt
SP
,
Brandt
DM
.
Intravenous drug use: a significant risk factor for Serratia bacteremia
.
Ther Adv Infect Dis
2022
;
9
:
20499361221078116
.

30

Baddour
LM
,
Sargent
SJ
.
Serious infections caused by coagulase-negative staphylococci in intravenous drug users
.
MO Med
1990
;
87
:
363
6
.

31

Miller
LG
,
Diep
BA
.
Colonization, fomites, and virulence: rethinking the pathogenesis of community-associated methicillin-resistant Staphylococcus aureus infection
.
Clin Infect Dis
2008
;
46
:
752
60
.

32

Russell
E
,
Sisco
E
,
Thomson
A
, et al.
Rapid analysis of drugs: a pilot surveillance system to detect changes in the illicit drug supply to guide timely harm reduction responses—eight syringe services programs, Maryland, November 2021–August 2022
.
MMWR Morb Mortal Wkly Rep
2023
;
72
:
458
62
.

33

Malayala
SV
,
Papudesi
BN
,
Bobb
R
,
Wimbush
A
.
Xylazine-induced skin ulcers in a person who injects drugs in Philadelphia, Pennsylvania, USA
.
Cureus
2022
;
14
:
e28160
.

34

Phillips
KA
,
Hirsch
GA
,
Epstein
DH
,
Preston
KL
.
Cardiac complications of unwitting co-injection of quinine/quinidine with heroin in an intravenous drug user
.
J Gen Intern Med
2012
;
27
:
1722
5
.

35

Marquez
J
,
Aguirre
L
,
Muñoz
C
,
Echeverri
A
,
Restrepo
M
,
Pinto
LF
.
Cocaine-levamisole-induced vasculitis/vasculopathy syndrome
.
Curr Rheumatol Rep
2017
;
19
:
36
.

36

Aspinall
EJ
,
Nambiar
D
,
Goldberg
DJ
, et al.
Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis
.
Int J Epidemiol
2013
;
43
:
235
48
.

37

Fernandes
RM
,
Cary
M
,
Duarte
G
, et al.
Effectiveness of needle and syringe programmes in people who inject drugs—an overview of systematic reviews
.
BMC Public Health
2017
;
17
:
309
.

38

Fernández-Viña
MH
,
Prood
NE
,
Herpolsheimer
A
,
Waimberg
J
,
Burris
S
.
State laws governing syringe services programs and participant syringe possession, 2014–2019
.
Public Health Rep
2020
;
135
(Suppl
1
):
128S
37S
.

Author notes

Potential conflicts of interest. All authors: No reported conflicts.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary data

Comments

0 Comments
Submit a comment
You have entered an invalid code
Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email.